BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Jones Trading Reiterates Hold Rating on BioLineRx (BLRX)
May 28, 2025 8:59 AM EDTJones Trading analyst Justin Walsh reiterated a Hold rating on BioLineRx (NASDAQ: BLRX).
The analyst comments "APHEXDA will provide a steady stream of royalties that support earlier stage development of assets expected to be in-licensed in 2025-2026, most likely in the oncology and/or... More
